Efroze Chemical Industries (Pvt.) Ltd. - Pharma Division

Belkins
Efroze Chemicals Industries (Private) Ltd. came into existence in 1968 with the Dedication to the Quality Pharmaceuticals, to empower mankind by promoting mental and physical wellbeing around the globe. Globally - The international footprint extends to 20 countries embracing different locales and cultures of CIS, Africa and Far East Asia.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ACERUS ANNOUNCES PRIVATE PLACEMENT AND REFINANCING TRANSACTIONS

BioSpace | February 13, 2020

news image

Acerus Pharmaceuticals Corporation Today announced that it has entered into agreements with First Generation Capital, Inc. (“First Generation”) in respect of an equity financing and debt-to-equity conversion by First Generation and with SWK Funding LLC (“SWK”) in respect of an amendment to the Company’s existing credit facility (the “SWK Facility”) with SWK (the “Refinancing Transactions”). First Generation is currently the Company’s la...

Read More

PHARMA TECH

MYMD PHARMACEUTICALS ANNOUNCES ISSUANCE OF U.S. PATENT COVERING LEAD DRUG CANDIDATE MYMD-1 IN A METHOD OF EXTENDING LIFESPAN

MyMD | November 24, 2021

news image

MyMD Pharmaceuticals, Inc. a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,179,382 B2, titled “Methods of Reversing Normal Aging Process and Extending Lifespan.” The allowed claims protect the use of MYMD-1 in a method designed to extend the lifespan of an individual. “This patent is a timely addition to ...

Read More

HEMOGENYX PHARMACEUTICALS PLC SIGNED BIOLOGICAL INVESTIGATION AND MATERIAL SUPPLY AGREEMENT WITH ELI LILLY

Hemogenyx Pharmaceuticals | July 14, 2020

news image

On 26 June 2020 the Company announced a Development Agreement with a global pharmaceutical company ("GlobalCo"). GlobalCo has now consented to the use of its name in the announcement, an updated version of which is shown below. Hemogenyx Pharmaceuticals plc is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement ("Agreement") with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company engage...

Read More

PHARMACY MARKET

AVACTA ANNOUNCES FDA APPROVAL OF ITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR AVA6000

Avacta | November 29, 2021

news image

Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase I clinical trial, ALS-6000-101, into clinical trial sites in the United States. AVA6000 is a novel f...

Read More
news image

ACERUS ANNOUNCES PRIVATE PLACEMENT AND REFINANCING TRANSACTIONS

BioSpace | February 13, 2020

Acerus Pharmaceuticals Corporation Today announced that it has entered into agreements with First Generation Capital, Inc. (“First Generation”) in respect of an equity financing and debt-to-equity conversion by First Generation and with SWK Funding LLC (“SWK”) in respect of an amendment to the Company’s existing credit facility (the “SWK Facility”) with SWK (the “Refinancing Transactions”). First Generation is currently the Company’s la...

Read More
news image

PHARMA TECH

MYMD PHARMACEUTICALS ANNOUNCES ISSUANCE OF U.S. PATENT COVERING LEAD DRUG CANDIDATE MYMD-1 IN A METHOD OF EXTENDING LIFESPAN

MyMD | November 24, 2021

MyMD Pharmaceuticals, Inc. a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent 11,179,382 B2, titled “Methods of Reversing Normal Aging Process and Extending Lifespan.” The allowed claims protect the use of MYMD-1 in a method designed to extend the lifespan of an individual. “This patent is a timely addition to ...

Read More
news image

HEMOGENYX PHARMACEUTICALS PLC SIGNED BIOLOGICAL INVESTIGATION AND MATERIAL SUPPLY AGREEMENT WITH ELI LILLY

Hemogenyx Pharmaceuticals | July 14, 2020

On 26 June 2020 the Company announced a Development Agreement with a global pharmaceutical company ("GlobalCo"). GlobalCo has now consented to the use of its name in the announcement, an updated version of which is shown below. Hemogenyx Pharmaceuticals plc is pleased to announce that it has signed a Biological Investigation and Material Supply Agreement ("Agreement") with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company engage...

Read More
news image

PHARMACY MARKET

AVACTA ANNOUNCES FDA APPROVAL OF ITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR AVA6000

Avacta | November 29, 2021

Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase I clinical trial, ALS-6000-101, into clinical trial sites in the United States. AVA6000 is a novel f...

Read More